KCT0004583已完成未知
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients with Advanced Solid Tumors and Pilot Expansion in Patients with Non-Small Cell Lung Cancer Harboring c-MET Dysregulation
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- Abion
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1. Only patients who meet all of the inclusion criteria and none of the exclusion criteria, as confirmed by the medical monitor at screening/day 1 of first dosing, will be eligible to receive ABN401. Signed informed consent before any study-specific screening procedures.
- •2. Male or female = 18 years of age or designated age of majority according to the regulatory authorities, whichever is higher.
- •3. Body weight = 40 kg and = 110 kg.
- •4. Eastern Cooperative Oncology Group (ECOG) performance status (PS), 0 or 1.
- •5. Diagnosis:
- •a. For the Phase 1 dose escalation, must have:
- •1) Histological or cytological diagnosis of melanoma or any type of carcinoma or sarcoma,
- •2) Refractory metastatic disease, or refractory locally advanced disease not amenable to local therapy,
- •3) Metastatic breast or prostate cancer may have bone-only disease.
- •b. For the Phase 1 extension (pilot expansion), must have NSCLC with cMET overexpression, MET amplification, or MET exon 14 skipping by
- •local biomarker assessment as defined and categorized in Section
- •6.3.4.1. The number of patients with only c-MET overexpression is limited to 50% of enrolled patients in that dosing cohort including escalation and extension.
- •6. Progressive disease:
- •Progressive disease on established standard medical anti-cancer therapy for his/her tumor type or intolerant to such therapy, or in the opinion of the investigator considered ineligible for a particular form of standard therapy on medical grounds.
- •7. At least one measurable lesion per response evaluation criteria in solid tumors (RECIST) 1.1, with the exception of bone-only disease (i.e., nonmeasurable disease per RECIST 1.1) with at least 1 radiological non-target lesion.
- •8. If not menopausal or surgically sterile, willing to practice at least one of the following highly effective methods of birth control for at least a (partner’s) menstrual cycle before and for 3 months after study drug administration:
- •a. True abstinence, when this is in line with the preferred and usual lifestyle of the patient, from sexual intercourse with a member of the opposite sex,
- •b. Sexual intercourse with vasectomized male/sterilized female partner,
- •c. Hormonal female contraceptive (oral, parenteral, intravaginal, implantable, or transdermal) for at least 3 consecutive months prior to investigational product administration (when not clinically contraindicated as in breast, ovarian and endometrial cancers),
- •d. Use of an intrauterine contraceptive device.
- •9. Resolution of prior-therapy-related AEs (including immune-related AEs but excluding alopecia) to = Grade 1 per CTCAE, and no treatment for these AEs for at least 2 weeks prior to the time of enrollment. Alopecia, sensory neuropathy Grade = 2, or other Grade = 2 AEs not constituting a safety risk based on investigator’s judgment are acceptable.
- •10. Minimum of 2 weeks since last dose of hormone therapy.
- •11. Minimum of > 2 weeks or > 5 half-lives (whichever is longer) between the start of study treatment since last dose of radiotherapy, chemotherapy or molecularly targeted agents or tyrosine kinase inhibitors; minimum of > 3 weeks of the start of study treatment since last dose of immunotherapy /monoclonal antibodies; > 6 weeks of the start of study treatment since the last dose of nitrosoureas, antibody-drug conjugates or radioactive isotopes.
- •12. Adequate organ function as indicated by the following laboratory values:
- •System Laboratory Value
- •Hematological:
- •Neutrophils
排除标准
- •Only patients who do not meet any of the following criteria, as confirmed by the medical monitor at screening/day 1 of first dosing, will be permitted to start
- •study treatment.
- •1. Previous severe hypersensitivity reaction to any component of ABN401. (The components are listed in Table 7).
- •2. Prior therapy
- •Treatment with more than 4 lines of prior systemic therapy for recurrent/metastatic disease. If the patient was treated with more than 4 lines but his/her condition is eligible to participate to the trial by the investigator’s judgement, the patient might be able to be enrolled to the trial under the medical monitor and the sponsor’s approval.
- •3. Genetic analysis:
- •Phase 1 Extension (pilot expansion) Cohort (s): existing data by genetic analysis of the patients tumor tissue that may result in an increased probability of being resistant to c-MET inhibitors, including 1) EGFR; 2) ALK; 3) ROS; 4) BRAF; 5) NTRK; 6) RET.
- •4. Chronic inflammatory liver condition. History or clinical evidence of any liver or biliary pathology including cirrhosis, infectious disease, inflammatory conditions, steatosis, or cholangitis (including ascending cholangitis, primary sclerosing cholangitis, obstruction, perforation, fistula of biliary tract, spasm of sphincter of Oddi, biliary cyst or biliary atresia).
- •5. Prior organ or stem cell transplant.
- •6. Known active infection with HIV, HTLV-1, hepatitis B virus (HBV), or hepatitis C virus (HCV):
- •a. Patients with a history of hepatitis B or C are allowed if HBV DNA or HCV RNA are undetectable,
- •b. Active infection with human immunodeficiency virus (HIV) and CD4+T-cell count <350/µL. Patients not on established ART for at least four weeks and having a detectable HIV viral load.
- •7. Symptomatic ascites or pleural effusion, unless clinically stable for at least two weeks following treatment for these conditions (including therapeutic thoraco- or paracentesis).
- •8. Known active central nervous system (CNS) primary tumor or metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks prior to first dose of study drug, have no evidence of new or enlarging brain metastases and are off steroids for at least 15 days prior to first dose of study drug.
- •9. Known history of a hematologic malignancy, malignant primary brain tumor, or of a second malignant primary solid tumor (other than that under study), unless the patient has undergone potentially curative therapy with no evidence of that disease for 3 years.
- •Note: The time requirement for no evidence of disease for 3 years does not
- •apply to patients who underwent successful definitive resection of nonmelanoma skin cancer, superficial bladder cancer, in situ cervical cancer, or other in situ cancers.
- •10. Active infection requiring therapy. However, subject with minor infections where oral antibiotic required, (e.g., urinary tract infection, Upper respiratory tract infection, etc.) could be eligible based on investigator’sjudgement.
- •11. Use of systemic corticosteroids > 10 mg/day prednisone or equivalent within 30 days or other immunosuppressive drugs within 30 days prior to first drug administration.
- •12. Received an investigational product or treated with an investigational device within 30 days prior to first drug administration.
- •13. Has been receiving: radiotherapy, chemotherapy, or molecularly-targeted agents or tyrosine kinase inhibitors within
研究者
相似试验
已完成
1 期
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid TumorsJPRN-jRCT2080224901AbbVie G.K.18
进行中（未招募）
1 期
A clinical trial to look at the safety and potential efficacy of FHD-609 in people with advanced synovial sarcomaAdvanced Synovial Sarcoma (SS)MedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-001488-25-ESFoghorn Therapeutics Inc.70
招募中
1 期
A clinical trial to look at the safety and potential efficacy of FHD-609 in people with advanced synovial sarcomaEUCTR2021-001488-25-ITFoghorn Therapeutics Inc.70
已完成
不适用
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286 in Subjects with Metastatic Uveal MelanomaNL-OMON53846Foghorn Therapeutics Inc.4
招募中
2 期
A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Adult Subjects with Advanced, Relapsed or Refractory Renal Cell Carcinoma (RCC) with Clear Cell Differentiatioclear cell renal cell carcinomakidney cancer10038364NL-OMON54482CRISPR Therapeutics AG8